Pittsburgh Man Has Survived Duchenne With Eteplirsen
A Pittsburgh resident has received weekly infusions of the exon-skipping drug eteplirsen since 2011.
Updated on Oct. 5, 2026 in Biotech
Billy Ellsworth, a 25-year-old Pittsburgh resident, continues his long-term treatment for Duchenne muscular dystrophy with the drug eteplirsen. He was among the original 12 clinical trial participants who began receiving the therapy in 2011, years before its 2016 FDA approval.
Why it matters
The treatment works as an exon-skipping drug that enables the body to produce dystrophin, a vital protein that protects muscle fibers which patients with Duchenne muscular dystrophy otherwise lack. This therapy has provided a lifeline for a small subset of patients, as the average life expectancy for those born in the 1990s was just 24 years.
Eteplirsen serves approximately 13% of Duchenne muscular dystrophy patients, a condition affecting 1 in 3,600 boys. The drug utilizes an exon-skipping mechanism to stimulate dystrophin protein production.
The players
Billy Ellsworth
He is a 25-year-old Pittsburgh resident who has been receiving eteplirsen infusions since joining a 2011 clinical trial.
UPMC Children's Hospital of Pittsburgh
This facility serves as the site for Billy Ellsworth's weekly drug infusions and clinical care.
The details
Billy Ellsworth, who resides in Kennedy, receives his infusions weekly at UPMC Children's Hospital of Pittsburgh. Despite using a wheelchair following broken femurs sustained after age 21, he continues to manage his condition through this established clinical protocol.
Timeline
1990-1999: Birth period for the study cohort.
2011: Billy Ellsworth entered the eteplirsen clinical trial.
2016: The FDA officially approved the use of eteplirsen.
2026: Billy Ellsworth reached age 25.
Fall 2026: A documentary titled The First Stories that Changed Duchenne will be released.
The Tech Race
The development and approval of eteplirsen marked a paradigm shift in genetic medicine, moving from purely symptomatic management to targeted molecular interventions. This therapy sets a benchmark for the ongoing race to develop similar exon-skipping drugs for various rare neuromuscular diseases.
Patients relying on specialized treatments like eteplirsen face ongoing logistical requirements, including regular hospital visits for weekly infusions. These medical routines necessitate careful management of health insurance coverage and consistent access to specialized care facilities.
The takeaway
The experience of patients like Billy Ellsworth underscores the critical role of long-term clinical trial participation in proving the efficacy of new treatments. Families navigating chronic conditions should maintain close coordination with specialized care centers to ensure continuity of care as new therapies emerge.
What happens next
A documentary film titled The First Stories that Changed Duchenne is scheduled for release in the fall of 2026.
Further reading
For more information on innovations in this field, visit our Biotech section.
